We use cookies for a better user experience. Read our Privacy Policy

I Agree

Intravenous Immunoglobulin Market

Intravenous Immunoglobulin Market (Indication: Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Intravenous Immunoglobulin Market Outlook 2031

  • The global intravenous immunoglobulin market was valued at US$ 11.2 Bn in 2021
  • It is estimated to grow at a CAGR of 7.3% from 2022 to 2031
  • The global intravenous immunoglobulin market is expected to reach value of US$ 20.5 Bn by the end of 2031

Analysts’ Viewpoint on Intravenous Immunoglobulin Market Scenario

The global intravenous immunoglobulin market is driven by the rise in the global prevalence of autoimmune diseases such as multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, and Kawasaki syndrome. The global intravenous immunoglobulin market is projected to witness significant growth over the next few years due to technological advancements leading to the development of new production and purification methods. Rapid increase in the number of neurological disorders, rise in the global geriatric population, and expansion of patient pool have fueled the demand for quick and reliable treatment measures. Furthermore, all companies should increase their R&D efforts in the development of novel products to broaden their revenue streams.

intravenous immunoglobulin market

Overview of Intravenous Immunoglobulin Market

Immunoglobulins are highly purified, sterile-specific medical therapy solutions containing gamma globulin G (IgG) in a concentration of 95% or more. These are manufactured from a highly refined pool of human plasma collected from at least 100 donors or more. Immunoglobulins can be administered through three different routes such as intramuscular, intravenous, and subcutaneous. The intramuscular route of administration is a relatively older method and is not preferred presently, as it is painful. Intravenous immunoglobulin has emerged as a boon in the last few decades for patients with compromised immune systems.

Request a sample to get extensive insights into the Intravenous Immunoglobulin Market

Rise in R&D Activities in Intravenous Immunoglobulin To Fuel Market Growth

Increasing adoption of immunoglobulin, along with a surge in frequency of product launches and prompt approval from government regulatory bodies across the world is expected to fuel the demand during the forecast period.  According to an October 2020 update by the National Institutes of Health, a clinical trial to test the safety, tolerability, and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral Remdesivir plus, a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, was initiated in 2020. The study was performed on hospitalized adults with COVID-19 in the U.S., Mexico, and 16 other countries on five continents.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and funded the phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC. The antibody solution that was tested in the ITAC trial is anti-coronavirus hyperimmune intravenous immunoglobulin or hIVIG. Moreover, the rise in the number of government initiatives supporting the usage of the intravenous mode of delivery for some medications propels the global market. For instance, in June 2021, the Ministry of Health and Family Welfare of Karnataka, India, decided to procure an intravenous immunoglobulin (IVIG) drug worth more than INR 10 Cr for emergency use among children.

Surge in incidence of Primary Immunodeficiency Diseases to Drive Global Market

In terms of indication, the global intravenous immunoglobulin market has been classified into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. The hypogammaglobinemia segment dominated the global market in 2021. This can be attributed to increase in incidence of primary immunodeficiency diseases (PID) across the globe. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).

Request a custom report on Intravenous Immunoglobulin Market

Preference for Hospital Treatment to Propel Demand for Intravenous Immunoglobulin in Hospitals

Based on end-user, the global intravenous immunoglobulin market has been divided into hospitals, clinics, and home care. The hospitals segment dominated the global intravenous immunoglobulin market in 2021, owing to rise in the number of patients opting for hospital treatment rather than standalone clinics. Moreover, patients receiving IVIG infusions at home have improved quality of life, as they get better control over day-to-day activities. For instance, IVIG infusions at home care have reduced scheduling clashes for patients.

COVID-19 Pandemic to Fuel Growth of Intravenous Immunoglobulin Market

The COVID-19 pandemic in its later phase is more likely to propel the growth of the global intravenous immunoglobulin market. December 2020 published article titled, 'COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience', stated that out of 100 individuals with primary immunodeficiency (PID), symptomatic secondary immunodeficiency (SID), autoinflammatory diseases, and C1 inhibitor deficiency, 70% were infected with the SARS-CoV-2 virus and 59% were admitted to hospitals, with 8% admitted to intensive care units. Therefore, an increase in immune-deficient individuals who are at higher risk of being infected with COVID-19 is likely to propel the global intravenous immunoglobulin market during the pandemic.

According to an October 2020 published article titled, 'The uSAGE of Intravenous Immunoglobulin Gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial', the administration of intravenous immunoglobulin in patients with severe COVID-19 infection was expected to enhance the clinical outcome and aid in a significant reduction of the mortality rate due to SARS-CoV2 viral infection. Hence, the global market is likely to witness strong growth during the pandemic.

Analysis of Key Players in Global Intravenous Immunoglobulin Market

This report profiles key players in the global intravenous immunoglobulin market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global intravenous immunoglobulin market is highly fragmented, with the presence of several international as well as regional players. Leading players operating in the global intravenous immunoglobulin market are Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V., among others.

The growing burden of target diseases such as primary immunodeficiency diseases is expected to fuel the growth of the market in the region. According to the National Institute of Allergy and Infectious Diseases, in 2020, more than 400 types of PIDs were diagnosed in the U.S., with more than 500,000 people affected by PIDs.

According to the USIDNET Registry, 2020, the frequency of severe combined immunodeficiency (SCID) among the population of the U.S. stood at 355. Moreover, increase in research & development activities and rapid product approvals are projected to fuel the growth of the intravenous immunoglobulin market growth in North America.

Key Developments in Global Intravenous Immunoglobulin Market

Key players in the global intravenous immunoglobulin market are expanding their market position by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market positions across the world. A few expansion strategies adopted by players operating in the global intravenous immunoglobulin market are:

  • In August 2021, Emergent BioSolutions, Inc., a multinational specialty biopharmaceutical company based in the U.S., reported the start of phase III clinical trial to evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (COVID-HIG) plasma-derived therapy as a capable outpatient treatment for patients with coronavirus (COVID-19) who are at high risk of progression to severe disease. Hence, the factors mentioned above are projected to boost the growth of the global intravenous immunoglobulin market during the forecast period.

The report on the global intravenous immunoglobulin market discusses individual strategies, followed by company profiles of manufacturers of intravenous immunoglobulin market products. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global intravenous immunoglobulin market.

Intravenous Immunoglobulin Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 11.2 Bn

Market Forecast Value in 2031

US$ 20.5 Bn

Growth Rate (CAGR)

7.3% from Year-to-Year

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market players - Competition matrix (by tier and size of companies)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Indication
    • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • Primary Humoral Immunodeficiency
    • Idiopathic Thrombocytopenic Purpura (ITP)
    • Guillain-Barre Syndrome
    • Myasthenia Gravis
    • Multifocal Motor Neuropathy (MMN)
    • Kawasaki Disease
    • Hypogammaglobulinemia
    • Chronic Lymphocytic Leukemia
    • Others
  • End-user
    • Hospitals
    • Clinics
    • Home Care

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

 

  • Baxalta Incorporated
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Behring LLC
  • Grifols S.A.
  • Kedrion S.p.A.
  • LFB Biomedicaments S.A.
  • Octapharma AG
  • Sanquin Plasma Products B.V.
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global intravenous immunoglobulin market in 2021?

The global intravenous immunoglobulin market was valued at US$ 11.2 Bn in 2021.

How big will be the intravenous immunoglobulin market in 2031?

The global intravenous immunoglobulin market will surpass US$ 20.5 Bn by 2031.

What is the CAGR of global intravenous immunoglobulin market 2022 to 2031?

The global intravenous immunoglobulin market is anticipated to record a CAGR of 7.3% from 2022 to 2031.

What are the prominent trends impacting the market growth?

Rise in prevalence of autoimmune diseases is expected to drive the global intravenous immunoglobulin market.

Which region is projected to hold large market share during the forecast period?

North America is expected to be a potential revenue generator for vendors during the forecast period.

Who are the prominent players in global intravenous immunoglobulin market?

Prominent players in the global intravenous immunoglobulin market include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V., among others.

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Intravenous Immunoglobulin (IVIG): Market Snapshot

    3.2. Market Share Analysis, by Region, 2017

    3.3. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map

4. Market Overview

    4.1. Indication Overview

    4.2. Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments

    4.3. Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators

5. Market Dynamics

    5.1. Drivers and Restraints Snapshot Analysis

    5.2. Drivers

        5.2.1. Rise in prevalence of autoimmune disorders

        5.2.2. Increase in global geriatric population

        5.2.3. Growing usage in off-label indications

        5.2.4. Improved technology for production and purification methods

        5.2.5. Favorable government initiatives and approvals

        5.2.6. Increase in health care spending & improving health care infrastructure

        5.2.7. Rise in incidence of hematological, neurological disorders

    5.3. Restraints

        5.3.1. High cost of treatment

        5.3.2. Chronic side effects

        5.3.3. Supply demand gaps

        5.3.4. Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications

    5.4. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis

    5.5. Opportunities

        5.5.1. Application in newer indications

        5.5.2. Increasing global plasma yield to offer significant opportunities to new entrants

    5.6. Key Trends

    5.7. Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031

    5.8. Value Chain Analysis

    5.9. Global Intravenous Immunoglobulin (IVIG) Market Outlook

6. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication

    6.1. Key Findings

    6.2. Introduction

    6.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication

    6.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication

        6.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

        6.4.2. Primary Humoral Immunodeficiency

        6.4.3. Idiopathic Thrombocytopenic Purpura (ITP)

        6.4.4. Guillain-Barre Syndrome

        6.4.5. Myasthenia Gravis

        6.4.6. Multifocal Motor Neuropathy (MMN)

        6.4.7. Kawasaki Disease

        6.4.8. Hypogammaglobulinemia

        6.4.9. Chronic Lymphocytic Leukemia

        6.4.10. Others

    6.5. Market Attractiveness Analysis, by Indication

    6.6. Key Trends

7. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user

    7.1. Key Findings

    7.2. Introduction

    7.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user

    7.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user

        7.4.1. Hospitals

        7.4.2. Clinics

        7.4.3. Home Care

    7.5. Market Attractiveness Analysis, by End-user

    7.6. Key Trends

8. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Region

    8.1. Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country

    8.2. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region

    8.3. Intravenous Immunoglobulin (IVIG) Market Forecast, by Region

    8.4. Market Attractiveness Analysis, by Region

9. North America Intravenous Immunoglobulin (IVIG) Market Analysis

    9.1. Key Findings

    9.2. Market Overview

    9.3. Market Analysis, by Indication

        9.3.1. Market Value Share Analysis, by Indication

        9.3.2. Market Size (US$ Mn) Forecast, by Indication

            9.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            9.3.2.2. Primary Humoral Immunodeficiency

            9.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)

            9.3.2.4. Guillain-Barre Syndrome

            9.3.2.5. Myasthenia Gravis

            9.3.2.6. Multifocal Motor Neuropathy (MMN)

            9.3.2.7. Kawasaki Disease

            9.3.2.8. Hypogammaglobulinemia

            9.3.2.9. Chronic Lymphocytic Leukemia

            9.3.2.10. Others

    9.4. Market Analysis, by End-user

        9.4.1. Market Value Share Analysis, by End-user

        9.4.2. Market Size (US$ Mn) Forecast, by End-user

            9.4.2.1. Hospitals

            9.4.2.2. Clinics

            9.4.2.3. Home Care

    9.5. Market Analysis, by Country

        9.5.1. Market Value Share Analysis, by Country

        9.5.2. Market Size (US$ Mn) Forecast, by Country, 2017–2031

            9.5.2.1. U.S.

            9.5.2.2. Canada

    9.6. Market Attractiveness Analysis

        9.6.1. By Indication

        9.6.2. By End-user

        9.6.3. By Country

    9.7. U.S. Intravenous Immunoglobulin (IVIG) Market Analysis

        9.7.1. Market Size (US$ Mn) Forecast, by Indication

            9.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            9.7.1.2. Primary Humoral Immunodeficiency

            9.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            9.7.1.4. Guillain-Barre Syndrome

            9.7.1.5. Myasthenia Gravis

            9.7.1.6. Multifocal Motor Neuropathy (MMN)

            9.7.1.7. Kawasaki Disease

            9.7.1.8. Hypogammaglobulinemia

            9.7.1.9. Chronic Lymphocytic Leukemia

            9.7.1.10. Others

        9.7.2. Market Size (US$ Mn) Forecast, by End-user

            9.7.2.1. Hospitals

            9.7.2.2. Clinics

            9.7.2.3. Home Care Settings

    9.8. Canada Intravenous Immunoglobulin (IVIG) Market Analysis

        9.8.1. Market Size (US$ Mn) Forecast, by Indication

            9.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            9.8.1.2. Primary Humoral Immunodeficiency

            9.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            9.8.1.4. Guillain-Barre Syndrome

            9.8.1.5. Myasthenia Gravis

            9.8.1.6. Multifocal Motor Neuropathy (MMN)

            9.8.1.7. Kawasaki Disease

            9.8.1.8. Hypogammaglobulinemia

            9.8.1.9. Chronic Lymphocytic Leukemia

            9.8.1.10. Others

        9.8.2. Market Size (US$ Mn) Forecast, by End-user

            9.8.2.1. Hospitals

            9.8.2.2. Clinics

            9.8.2.3. Home Care Settings

10. Europe Intravenous Immunoglobulin (IVIG) Market Analysis

    10.1. Key Findings

    10.2. Market Overview

    10.3. Market Analysis, by Indication

        10.3.1. Market Value Share Analysis, by Indication

        10.3.2. Market Size (US$ Mn) Forecast, by Indication

            10.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            10.3.2.2. Primary Humoral Immunodeficiency

            10.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)

            10.3.2.4. Guillain-Barre Syndrome

            10.3.2.5. Myasthenia Gravis

            10.3.2.6. Multifocal Motor Neuropathy (MMN)

            10.3.2.7. Kawasaki Disease

            10.3.2.8. Hypogammaglobulinemia

            10.3.2.9. Chronic Lymphocytic Leukemia

            10.3.2.10. Others

    10.4. Market Analysis, by End-user

        10.4.1. Market Value Share Analysis, by End-user

        10.4.2. Market Size (US$ Mn) Forecast, by End-user

            10.4.2.1. Hospitals

            10.4.2.2. Clinics

            10.4.2.3. Home Care

    10.5. Market Analysis, by Country/Sub-region

        10.5.1. Market Value Share Analysis, by Country/Sub-region

        10.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            10.5.2.1. U.K.

            10.5.2.2. Germany

            10.5.2.3. France

            10.5.2.4. Spain

            10.5.2.5. Italy

            10.5.2.6. Rest of Europe

    10.6. Market Attractiveness Analysis

        10.6.1. By Indication

        10.6.2. By End-user

        10.6.3. By Country/Sub-region

    10.7. U.K. Intravenous Immunoglobulin (IVIG) Market Analysis

        10.7.1. Market Size (US$ Mn) Forecast, by Indication

            10.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            10.7.1.2. Primary Humoral Immunodeficiency

            10.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            10.7.1.4. Guillain-Barre Syndrome

            10.7.1.5. Myasthenia Gravis

            10.7.1.6. Multifocal Motor Neuropathy (MMN)

            10.7.1.7. Kawasaki Disease

            10.7.1.8. Hypogammaglobulinemia

            10.7.1.9. Chronic Lymphocytic Leukemia

            10.7.1.10. Others

        10.7.2. Market Size (US$ Mn) Forecast, by End-user

            10.7.2.1. Hospitals

            10.7.2.2. Clinics

            10.7.2.3. Home Care Settings

    10.8. Germany Intravenous Immunoglobulin (IVIG) Market Analysis

        10.8.1. Market Size (US$ Mn) Forecast, by Indication

            10.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            10.8.1.2. Primary Humoral Immunodeficiency

            10.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            10.8.1.4. Guillain-Barre Syndrome

            10.8.1.5. Myasthenia Gravis

            10.8.1.6. Multifocal Motor Neuropathy (MMN)

            10.8.1.7. Kawasaki Disease

            10.8.1.8. Hypogammaglobulinemia

            10.8.1.9. Chronic Lymphocytic Leukemia

            10.8.1.10. Others

        10.8.2. Market Size (US$ Mn) Forecast, by End-user

            10.8.2.1. Hospitals

            10.8.2.2. Clinics

            10.8.2.3. Home Care Settings

    10.9. France Intravenous Immunoglobulin (IVIG) Market Analysis

        10.9.1. Market Size (US$ Mn) Forecast, by Indication

            10.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            10.9.1.2. Primary Humoral Immunodeficiency

            10.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            10.9.1.4. Guillain-Barre Syndrome

            10.9.1.5. Myasthenia Gravis

            10.9.1.6. Multifocal Motor Neuropathy (MMN)

            10.9.1.7. Kawasaki Disease

            10.9.1.8. Hypogammaglobulinemia

            10.9.1.9. Chronic Lymphocytic Leukemia

            10.9.1.10. Others

        10.9.2. Market Size (US$ Mn) Forecast, by End-user

            10.9.2.1. Hospitals

            10.9.2.2. Clinics

            10.9.2.3. Home Care Settings

    10.10. Spain Intravenous Immunoglobulin (IVIG) Market Analysis

        10.10.1. Market Size (US$ Mn) Forecast, by Indication

            10.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            10.10.1.2. Primary Humoral Immunodeficiency

            10.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            10.10.1.4. Guillain-Barre Syndrome

            10.10.1.5. Myasthenia Gravis

            10.10.1.6. Multifocal Motor Neuropathy (MMN)

            10.10.1.7. Kawasaki Disease

            10.10.1.8. Hypogammaglobulinemia

            10.10.1.9. Chronic Lymphocytic Leukemia

            10.10.1.10. Others

        10.10.2. Market Size (US$ Mn) Forecast, by End-user

            10.10.2.1. Hospitals

            10.10.2.2. Clinics

            10.10.2.3. Home Care Settings

    10.11. Italy Intravenous Immunoglobulin (IVIG) Market Analysis

        10.11.1. Market Size (US$ Mn) Forecast, by Indication

            10.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            10.11.1.2. Primary Humoral Immunodeficiency

            10.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            10.11.1.4. Guillain-Barre Syndrome

            10.11.1.5. Myasthenia Gravis

            10.11.1.6. Multifocal Motor Neuropathy (MMN)

            10.11.1.7. Kawasaki Disease

            10.11.1.8. Hypogammaglobulinemia

            10.11.1.9. Chronic Lymphocytic Leukemia

            10.11.1.10. Others

        10.11.2. Market Size (US$ Mn) Forecast, by End-user

            10.11.2.1. Hospitals

            10.11.2.2. Clinics

            10.11.2.3. Home Care Settings

    10.12. Rest of Europe Intravenous Immunoglobulin (IVIG) Market Analysis

        10.12.1. Market Size (US$ Mn) Forecast, by Indication

            10.12.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            10.12.1.2. Primary Humoral Immunodeficiency

            10.12.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            10.12.1.4. Guillain-Barre Syndrome

            10.12.1.5. Myasthenia Gravis

            10.12.1.6. Multifocal Motor Neuropathy (MMN)

            10.12.1.7. Kawasaki Disease

            10.12.1.8. Hypogammaglobulinemia

            10.12.1.9. Chronic Lymphocytic Leukemia

            10.12.1.10. Others

        10.12.2. Market Size (US$ Mn) Forecast, by End-user

            10.12.2.1. Hospitals

            10.12.2.2. Clinics

            10.12.2.3. Home Care Settings

11. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis

    11.1. Key Findings

    11.2. Market Overview

    11.3. Market Analysis, by Indication

        11.3.1. Market Value Share Analysis, by Indication

        11.3.2. Market Size (US$ Mn) Forecast, by Indication

            11.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            11.3.2.2. Primary Humoral Immunodeficiency

            11.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)

            11.3.2.4. Guillain-Barre Syndrome

            11.3.2.5. Myasthenia Gravis

            11.3.2.6. Multifocal Motor Neuropathy (MMN)

            11.3.2.7. Kawasaki Disease

            11.3.2.8. Hypogammaglobulinemia

            11.3.2.9. Chronic Lymphocytic Leukemia

            11.3.2.10. Others

    11.4. Market Analysis, by End-user

        11.4.1. Market Value Share Analysis, by End-user

        11.4.2. Market Size (US$ Mn) Forecast, by End-user

            11.4.2.1. Hospitals

            11.4.2.2. Clinics

            11.4.2.3. Home Care

    11.5. Market Analysis, by Country/Sub-region

        11.5.1. Market Value Share Analysis, by Country/Sub-region

        11.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            11.5.2.1. China

            11.5.2.2. Japan

            11.5.2.3. Australia

            11.5.2.4. India

            11.5.2.5. Rest of Asia Pacific

    11.6. Market Attractiveness Analysis

        11.6.1. By Indication

        11.6.2. By End-user

        11.6.3. By Country/Sub-region

    11.7. China Intravenous Immunoglobulin (IVIG) Market Analysis

        11.7.1. Market Size (US$ Mn) Forecast, by Indication

            11.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            11.7.1.2. Primary Humoral Immunodeficiency

            11.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            11.7.1.4. Guillain-Barre Syndrome

            11.7.1.5. Myasthenia Gravis

            11.7.1.6. Multifocal Motor Neuropathy (MMN)

            11.7.1.7. Kawasaki Disease

            11.7.1.8. Hypogammaglobulinemia

            11.7.1.9. Chronic Lymphocytic Leukemia

            11.7.1.10. Others

        11.7.2. Market Size (US$ Mn) Forecast, by End-user

            11.7.2.1. Hospitals

            11.7.2.2. Clinics

            11.7.2.3. Home Care Settings

    11.8. Japan Intravenous Immunoglobulin (IVIG) Market Analysis

        11.8.1. Market Size (US$ Mn) Forecast, by Indication

            11.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            11.8.1.2. Primary Humoral Immunodeficiency

            11.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            11.8.1.4. Guillain-Barre Syndrome

            11.8.1.5. Myasthenia Gravis

            11.8.1.6. Multifocal Motor Neuropathy (MMN)

            11.8.1.7. Kawasaki Disease

            11.8.1.8. Hypogammaglobulinemia

            11.8.1.9. Chronic Lymphocytic Leukemia

            11.8.1.10. Others

        11.8.2. Market Size (US$ Mn) Forecast, by End-user

            11.8.2.1. Hospitals

            11.8.2.2. Clinics

            11.8.2.3. Home Care Settings

    11.9. Australia Intravenous Immunoglobulin (IVIG) Market Analysis

        11.9.1. Market Size (US$ Mn) Forecast, by Indication

            11.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            11.9.1.2. Primary Humoral Immunodeficiency

            11.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            11.9.1.4. Guillain-Barre Syndrome

            11.9.1.5. Myasthenia Gravis

            11.9.1.6. Multifocal Motor Neuropathy (MMN)

            11.9.1.7. Kawasaki Disease

            11.9.1.8. Hypogammaglobulinemia

            11.9.1.9. Chronic Lymphocytic Leukemia

            11.9.1.10. Others

        11.9.2. Market Size (US$ Mn) Forecast, by End-user

            11.9.2.1. Hospitals

            11.9.2.2. Clinics

            11.9.2.3. Home Care Settings

    11.10. India Intravenous Immunoglobulin (IVIG) Market Analysis

        11.10.1. Market Size (US$ Mn) Forecast, by Indication

            11.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            11.10.1.2. Primary Humoral Immunodeficiency

            11.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            11.10.1.4. Guillain-Barre Syndrome

            11.10.1.5. Myasthenia Gravis

            11.10.1.6. Multifocal Motor Neuropathy (MMN)

            11.10.1.7. Kawasaki Disease

            11.10.1.8. Hypogammaglobulinemia

            11.10.1.9. Chronic Lymphocytic Leukemia

            11.10.1.10. Others

        11.10.2. Market Size (US$ Mn) Forecast, by End-user

            11.10.2.1. Hospitals

            11.10.2.2. Clinics

            11.10.2.3. Home Care Settings

    11.11. Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis

        11.11.1. Market Size (US$ Mn) Forecast, by Indication

            11.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            11.11.1.2. Primary Humoral Immunodeficiency

            11.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            11.11.1.4. Guillain-Barre Syndrome

            11.11.1.5. Myasthenia Gravis

            11.11.1.6. Multifocal Motor Neuropathy (MMN)

            11.11.1.7. Kawasaki Disease

            11.11.1.8. Hypogammaglobulinemia

            11.11.1.9. Chronic Lymphocytic Leukemia

            11.11.1.10. Others

        11.11.2. Market Size (US$ Mn) Forecast, by End-user

            11.11.2.1. Hospitals

            11.11.2.2. Clinics

            11.11.2.3. Home Care Settings

12. Latin America Intravenous Immunoglobulin (IVIG) Market Analysis

    12.1. Key Findings

    12.2. Market Overview

    12.3. Market Analysis, by Indication

        12.3.1. Market Value Share Analysis, by Indication

        12.3.2. Market Size (US$ Mn) Forecast, by Indication

            12.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            12.3.2.2. Primary Humoral Immunodeficiency

            12.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)

            12.3.2.4. Guillain-Barre Syndrome

            12.3.2.5. Myasthenia Gravis

            12.3.2.6. Multifocal Motor Neuropathy (MMN)

            12.3.2.7. Kawasaki Disease

            12.3.2.8. Hypogammaglobulinemia

            12.3.2.9. Chronic Lymphocytic Leukemia

            12.3.2.10. Others

    12.4. Market Analysis, by End-user

        12.4.1. Market Value Share Analysis, by End-user

        12.4.2. Market Size (US$ Mn) Forecast, by End-user

            12.4.2.1. Hospitals

            12.4.2.2. Clinics

            12.4.2.3. Home Care

    12.5. Market Analysis, by Country/Sub-region

        12.5.1. Market Value Share Analysis, by Country/Sub-region

        12.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            12.5.2.1. Brazil

            12.5.2.2. Mexico

            12.5.2.3. Rest of Latin America

    12.6. Market Attractiveness Analysis

        12.6.1. By Indication

        12.6.2. By End-user

        12.6.3. By Country/Sub-region

    12.7. Brazil Intravenous Immunoglobulin (IVIG) Market Analysis

        12.7.1. Market Size (US$ Mn) Forecast, by Indication

            12.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            12.7.1.2. Primary Humoral Immunodeficiency

            12.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            12.7.1.4. Guillain-Barre Syndrome

            12.7.1.5. Myasthenia Gravis

            12.7.1.6. Multifocal Motor Neuropathy (MMN)

            12.7.1.7. Kawasaki Disease

            12.7.1.8. Hypogammaglobulinemia

            12.7.1.9. Chronic Lymphocytic Leukemia

            12.7.1.10. Others

        12.7.2. Market Size (US$ Mn) Forecast, by End-user

            12.7.2.1. Hospitals

            12.7.2.2. Clinics

            12.7.2.3. Home Care Settings

    12.8. Mexico Intravenous Immunoglobulin (IVIG) Market Analysis

        12.8.1. Market Size (US$ Mn) Forecast, by Indication

            12.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            12.8.1.2. Primary Humoral Immunodeficiency

            12.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            12.8.1.4. Guillain-Barre Syndrome

            12.8.1.5. Myasthenia Gravis

            12.8.1.6. Multifocal Motor Neuropathy (MMN)

            12.8.1.7. Kawasaki Disease

            12.8.1.8. Hypogammaglobulinemia

            12.8.1.9. Chronic Lymphocytic Leukemia

            12.8.1.10. Others

        12.8.2. Market Size (US$ Mn) Forecast, by End-user

            12.8.2.1. Hospitals

            12.8.2.2. Clinics

            12.8.2.3. Home Care Settings

    12.9. Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Analysis

        12.9.1. Market Size (US$ Mn) Forecast, by Indication

            12.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            12.9.1.2. Primary Humoral Immunodeficiency

            12.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            12.9.1.4. Guillain-Barre Syndrome

            12.9.1.5. Myasthenia Gravis

            12.9.1.6. Multifocal Motor Neuropathy (MMN)

            12.9.1.7. Kawasaki Disease

            12.9.1.8. Hypogammaglobulinemia

            12.9.1.9. Chronic Lymphocytic Leukemia

            12.9.1.10. Others

        12.9.2. Market Size (US$ Mn) Forecast, by End-user

            12.9.2.1. Hospitals

            12.9.2.2. Clinics

            12.9.2.3. Home Care Settings

13. Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis

    13.1. Key Findings

    13.2. Market Overview

    13.3. Market Analysis, by Indication

        13.3.1. Market Value Share Analysis, by Indication

        13.3.2. Market Size (US$ Mn) Forecast, by Indication

            13.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            13.3.2.2. Primary Humoral Immunodeficiency

            13.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)

            13.3.2.4. Guillain-Barre Syndrome

            13.3.2.5. Myasthenia Gravis

            13.3.2.6. Multifocal Motor Neuropathy (MMN)

            13.3.2.7. Kawasaki Disease

            13.3.2.8. Hypogammaglobulinemia

            13.3.2.9. Chronic Lymphocytic Leukemia

            13.3.2.10. Others

    13.4. Market Analysis, by End-user

        13.4.1. Market Value Share Analysis, by End-user

        13.4.2. Market Size (US$ Mn) Forecast, by End-user

            13.4.2.1. Hospitals

            13.4.2.2. Clinics

            13.4.2.3. Home Care

    13.5. Market Analysis, by Country/Sub-region

        13.5.1. Market Value Share Analysis, by Country/Sub-region

        13.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

            13.5.2.1. GCC Countries

            13.5.2.2. South Africa

            13.5.2.3. Rest of Middle East & Africa

    13.6. Market Attractiveness Analysis

        13.6.1. By Indication

        13.6.2. By End-user

        13.6.3. By Country/Sub-region

    13.7. GCC Countries Intravenous Immunoglobulin (IVIG) Market Analysis

        13.7.1. Market Size (US$ Mn) Forecast, by Indication

            13.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            13.7.1.2. Primary Humoral Immunodeficiency

            13.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            13.7.1.4. Guillain-Barre Syndrome

            13.7.1.5. Myasthenia Gravis

            13.7.1.6. Multifocal Motor Neuropathy (MMN)

            13.7.1.7. Kawasaki Disease

            13.7.1.8. Hypogammaglobulinemia

            13.7.1.9. Chronic Lymphocytic Leukemia

            13.7.1.10. Others

        13.7.2. Market Size (US$ Mn) Forecast, by End-user

            13.7.2.1. Hospitals

            13.7.2.2. Clinics

            13.7.2.3. Home Care Settings

    13.8. South Africa Intravenous Immunoglobulin (IVIG) Market Analysis

        13.8.1. Market Size (US$ Mn) Forecast, by Indication

            13.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            13.8.1.2. Primary Humoral Immunodeficiency

            13.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            13.8.1.4. Guillain-Barre Syndrome

            13.8.1.5. Myasthenia Gravis

            13.8.1.6. Multifocal Motor Neuropathy (MMN)

            13.8.1.7. Kawasaki Disease

            13.8.1.8. Hypogammaglobulinemia

            13.8.1.9. Chronic Lymphocytic Leukemia

            13.8.1.10. Others

        13.8.2. Market Size (US$ Mn) Forecast, by End-user

            13.8.2.1. Hospitals

            13.8.2.2. Clinics

            13.8.2.3. Home Care Settings

    13.9. Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis

        13.9.1. Market Size (US$ Mn) Forecast, by Indication

            13.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

            13.9.1.2. Primary Humoral Immunodeficiency

            13.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)

            13.9.1.4. Guillain-Barre Syndrome

            13.9.1.5. Myasthenia Gravis

            13.9.1.6. Multifocal Motor Neuropathy (MMN)

            13.9.1.7. Kawasaki Disease

            13.9.1.8. Hypogammaglobulinemia

            13.9.1.9. Chronic Lymphocytic Leukemia

            13.9.1.10. Others

        13.9.2. Market Size (US$ Mn) Forecast, by End-user

            13.9.2.1. Hospitals

            13.9.2.2. Clinics

            13.9.2.3. Home Care Settings

14. Company Profiles

    14.1. Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2021)

    14.2. Competition Matrix

    14.3. Company Profiles

        14.3.1. Baxalta Incorporated

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Financial Overview

            14.3.1.3. Product Portfolio

            14.3.1.4. SWOT Analysis

            14.3.1.5. Strategic Overview

        14.3.2. Biotest AG

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Financial Overview

            14.3.2.3. Product Portfolio

            14.3.2.4. SWOT Analysis

            14.3.2.5. Strategic Overview

        14.3.3. China Biologic Products, Inc.

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Financial Overview

            14.3.3.3. Product Portfolio

            14.3.3.4. SWOT Analysis

            14.3.3.5. Strategic Overview

        14.3.4. CSL Behring LLC

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Financial Overview

            14.3.4.3. Product Portfolio

            14.3.4.4. SWOT Analysis

            14.3.4.5. Strategic Overview

        14.3.5. Grifols S.A.

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Financial Overview

            14.3.5.3. Product Portfolio

            14.3.5.4. SWOT Analysis

            14.3.5.5. Strategic Overview

        14.3.6. Kedrion S.p.A.

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Financial Overview

            14.3.6.3. Product Portfolio

            14.3.6.4. SWOT Analysis

            14.3.6.5. Strategic Overview

        14.3.7. LFB Biomedicaments S.A.

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Financial Overview

            14.3.7.3. Product Portfolio

            14.3.7.4. SWOT Analysis

            14.3.7.5. Strategic Overview

        14.3.8. Octapharma AG

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Financial Overview

            14.3.8.3. Product Portfolio

            14.3.8.4. SWOT Analysis

            14.3.8.5. Strategic Overview

        14.3.9. Sanquin Plasma Products B.V.

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Financial Overview

            14.3.9.3. Product Portfolio

            14.3.9.4. SWOT Analysis

            14.3.9.5. Strategic Overview

List of Tables

Table 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 02: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 03: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 05: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 06: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 07: U.S. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 08: U.S. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Canada Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 10: Canada Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 11: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: U.K. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 15: U.K. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Germany Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 17: Germany Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 18: France Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 19: France Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Spain Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 21: Spain Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 22: Italy Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 23: Italy Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 24: Rest of Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 25: Rest of Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 26: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 27: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 28: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 29: China Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 30: China Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 31: Japan Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 32: Japan Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 33: India Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 34: India Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 35: Australia & New Zealand Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 36: Australia & New Zealand Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 37: Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 38: Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 39: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 40: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 41: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 42: Brazil Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 43: Brazil Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 44: Mexico Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 45: Mexico Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 46: Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 47: Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 48: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication Type, 2017–2031

Table 49: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 50: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 51: GCC Countries Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 52: GCC Countries Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 53: South Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 54: South Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 55: Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 56: Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031

Figure 02: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication, 2017 and 2031

Figure 03: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, US$ Mn, 2017–2031

Figure 04: Global Primary Humoral Immunodeficiency Market Revenue, US$ Mn, 2017–2031

Figure 05: Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, US$ Mn, 2017–2031

Figure 06: Global Guillain-Barre Syndrome Market Revenue, US$ Mn, 2017–2031

Figure 07: Global Myasthenia Gravis Market Revenue, US$ Mn, 2017–2031

Figure 08: Global Multifocal Motor Neuropathy (MMN) Market Revenue, US$ Mn, 2017–2031

Figure 09: Global Kawasaki Disease Market Revenue, US$ Mn, 2017–2031

Figure 10: Global Hypogammaglobulinemia Market Revenue, US$ Mn, 2017–2031

Figure 11: Global Chronic Lymphocytic Leukemia Market Revenue, US$ Mn, 2017–2031

Figure 12: Global Other Indications Market Revenue, US$ Mn, 2017–2031

Figure 13: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Indication

Figure 14: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user, 2017 and 2031

Figure 15: Global Hospitals Market Revenue, US$ Mn,

Figure 16: Global Clinics Market Revenue, US$ Mn,

Figure 17: Global Home Care Market Revenue, US$ Mn, 2017–2031

Figure 18: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by End-user

Figure 19: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region, 2017 and 2031

Figure 20: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Region

Figure 21: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031

Figure 22: North America Market Attractiveness Analysis, by Country

Figure 23: North America Market Value Share Analysis, by Indication, 2017 and 2031

Figure 24: North America Market Value Share Analysis, by End-user, 2017 and 2031

Figure 25: North America Market Value Share Analysis, by Country, 2017 and 2031

Figure 26: North America Market Attractiveness Analysis, by Indication

Figure 27: North America Market Attractiveness Analysis, by End-user

Figure 28: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031

Figure 29: Europe Market Attractiveness Analysis, by Country/Sub-region

Figure 30: Europe Market Value Share Analysis, by Indication, 2017 and 2031

Figure 31: Europe Market Value Share Analysis, by End-user, 2017 and 2031

Figure 32: Europe Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 33: Europe Market Attractiveness Analysis, by Indication

Figure 34: Europe Market Attractiveness Analysis, by End-user

Figure 35: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031

Figure 36: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region

Figure 37: Asia Pacific Market Value Share Analysis, by Indication, 2017 and 2031

Figure 38: Asia Pacific Market Value Share Analysis, by End-user, 2017 and 2031

Figure 39: Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 40: Asia Pacific Market Attractiveness Analysis, by Indication

Figure 41: Asia Pacific Market Attractiveness Analysis, by End-user

Figure 42: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031

Figure 43: Latin America Market Attractiveness Analysis, by Country/Sub-region

Figure 44: Latin America Market Value Share Analysis, by Indication, 2017 and 2031

Figure 45: Latin America Market Value Share Analysis, by End-user, 2017 and 2031

Figure 46: Latin America Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 47: Latin America Market Attractiveness Analysis, by Indication

Figure 48: Latin America Market Attractiveness Analysis, by End-user

Figure 49: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031

Figure 50: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region

Figure 51: Middle East & Africa Market Value Share Analysis, by Indication, 2017 and 2031

Figure 52: Middle East & Africa Market Value Share Analysis, by End-user, 2017 and 2031

Figure 53: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 54: Middle East & Africa Market Attractiveness Analysis, by Indication

Figure 55: Middle East & Africa Market Attractiveness Analysis, by End-user

Figure 56: Global Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2021)

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved